Apimeds names Eric Sherb as CFO after Erick Frim resigns

Apimeds Pharmaceuticals US, Inc. reported in a Form 8-K that Erick Frim notified the company on September 29, 2026 of his resignation as Interim Chief Financial Officer, effective immediately.¹ Frim had been reappointed to the interim CFO post on March 30, 2026.¹ The filing stated that his departure was not tied to any disagreement with the company over its operations, policies, or practices.¹

The board appointed Eric Sherb, 40, to serve as Chief Financial Officer, with the move taking effect October 1, 2026. Sherb will hold the roles of principal financial officer and principal accounting officer for the company.¹ According to the filing, he is a Certified Public Accountant with more than 18 years of experience in capital markets work.¹ He started an accounting and advisory firm, EMS Consulting Services, LLC, in January 2019 and has run it as Principal since then.¹ Through that firm, Sherb has supported private and public companies on CFO services, complex technical accounting, U.S. GAAP and SEC reporting, PCAOB audit coordination, IPO readiness, M&A, corporate governance, and accounting oversight.¹ Earlier in his career, he worked at PricewaterhouseCoopers LLP in New York before moving to mid-market accounting and advisory firms serving capital markets clients.¹ He earned his degree from Emory University.¹

The filing also noted that since February 2026, Sherb has served as fractional CFO of MindWave Innovations Inc., a wholly owned subsidiary of Apimeds, an arrangement that will end once he takes the new CFO post.¹ Under his new employment agreement, Sherb will be paid a base salary of $60,000 per year.¹ The company said there is no arrangement or understanding with any other person that led to his selection for the role,¹ and that he has no reportable related-party transactions with the company and no family ties to its board or executive officers.¹